Site icon The East County Gazette

Weight Loss Medicine Gets Sold Out! Is it Effective?

Wegovy, a weight loss medication manufactured by Novo Nordisk quickly sold out its initial stocks in the United States shortly after receiving FDA approval. 

Novo Nordisk reported a 15 percent increase in company sales in Q3, after introducing Wegovy, because of the popularity of the medication. 

“In the US, the initial demand for Wegovy has significantly exceeded our expectations, underscoring the high unmet need for people living with obesity,” said Novo Nordisk Chief Executive Officer Lars Fruergaard Jrgensen.

Read more: Deadly Bacteria Found in Walmart Products?

Initial studies indicated that the use of Wegovy by obese subjects resulted in an approximate 15-percent reduction in weight over 12 months.

Wegovy acts as a natural hormone in the body that acts on your brain to regulate patient’s appetite and food intake. By acting like GLP-1, Wegovy lowers your appetite and how much food patients need to eat to help them lose weight.

The typical starting dose is 0.25 mg injected under the skin once a week for 4 weeks (1 month). Patients will use a higher dose every 4 weeks until you reach a maintenence dose of 2.4 mg once a week. 

After about 1 year (68 weeks), people who took the maintenance dose of Wegovy (semaglutide) along with a lower-calorie diet and exercise lost an average of 10% to 16% of their starting body weight compared to those following a lower-calorie diet and exercise plan only.

Read more: New Virus is affecting kids in America. Should You be Worried?

The site GoodRX gives important tips on the use of Wegovy, which are as follows: 

Read more: Broken Heart Syndrome: More Common in Older Women?

Read more: COVID-19 Causes Diabetes? Read What Researchers Found Out

The lowest GoodRx price for the most common version of Wegovy is around $1,319.34, 41% off the average retail price of $2,262.84.

Keep up with more news here at the East County Gazette. 

Exit mobile version